Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - lutetium (177lu) oxodotreotide - injection, solution (radiopharmaceutical) - lutetium (177lu) oxodotreotide 370 mbq/ml

European Union - English - EMA (European Medicines Agency)

advanced accelerator applications - lutetium (177lu) oxodotreotide - neuroendocrine tumors - other therapeutic radiopharmaceuticals - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep‑nets) in adults.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - lutetium (177lu) oxodotreotide - solution - 370mbq - lutetium (177lu) oxodotreotide 370mbq - antineoplastic agents

Israel - English - Ministry of Health

novartis israel ltd - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.

Israel - English - Ministry of Health

marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.

Israel - English - Ministry of Health

marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.

Israel - English - Ministry of Health

s.r.y. (medical services ) ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 600 mbq/ml - lutetium (177lu) oxodotreotide - for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep-nets) in adults.